阻断免疫检查点的纳米穿越血脑屏障,阻止脑瘤生长
Minseong Kim1,2,3, Hee Jung Yoon4, Chanju Lee4
1Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu 41944, Republic of Korea.
ACS biomaterials science & engineering
|December 27, 2023
概括
携带PD-L1阻断的新型费里丁纳米有效地穿越血脑屏障以向质母细胞瘤. 这种方法克服了关键的挑战,并通过恢复T细胞活动来治疗脑瘤的希望.
科学领域:
- 神经瘤学神经瘤学
- 纳米技术纳米技术
- 免疫治疗是一种免疫疗法.
背景情况:
- 质母细胞瘤 (GBM) 是一种高度攻击性的脑瘤,患者的存活率很低.
- 目前的免疫检查点阻断 (ICB) 疗法在GBM中显示出有限的疗效,原因是血液-大脑屏障 (BBB) 和瘤的免疫抑制微环境中药物输送的挑战.
研究的目的:
- 开发一种新的治疗策略,通过调节免疫微环境,可以克服BBB并准GBM.
- 创建和评估BBB-透的,基于费里的纳米,显示PD-L1阻断,用于GBM治疗.
主要方法:
- 在24个子单元纳米中设计了人类费里重链,显示了PD-L1阻断 (PD-L1pep) 的24个副本.
- 在结肠癌全移植模型中评估瘤向和抗瘤活性.
- 评估了BBB透率,GBM向性和瘤生长抑制在正位 intracranial GBM模型中.
- 在体外研究了PD-L1pep铁素纳米对PD-1/PD-L1相互作用和T细胞活性的影响.
主要成果:
- 在结肠癌模型中,PD-L1pep铁素纳米显示了瘤向和抗瘤效应.
- 纳米有效地穿越了BBB并准了内GBM,显著抑制了瘤的生长.
- 实验室研究表明,PD-L1pep铁素纳米阻断了PD-1/PD-L1相互作用,并恢复了T细胞活性.
结论:
- 基于费里的纳米显示PD-L1阻断是一种有希望的策略,以克服BBB在脑瘤治疗中的局限性.
- 这种新的方法有可能通过增强抗瘤免疫反应来治疗质母细胞瘤.
相关概念视频
The Blood-brain Barrier
47.4K
Overview
47.4K
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


